Shanghai Universal Biotech Co Ltd
SZSE:301166
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (13.3), the stock would be worth ¥5.06 (84% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 80.5 | ¥30.65 |
0%
|
| 3-Year Average | 13.3 | ¥5.06 |
-84%
|
| 5-Year Average | 11.9 | ¥4.51 |
-85%
|
| Industry Average | 20.3 | ¥7.74 |
-75%
|
| Country Average | 20.8 | ¥7.92 |
-74%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
S
|
Shanghai Universal Biotech Co Ltd
SZSE:301166
|
2.7B CNY | 80.5 | -139.7 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | 9.9 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 15.4 | 36.9 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.2B USD | 15.1 | 36.4 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.2B USD | 8.6 | 28.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 55.8 | 34.9 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.6B CNY | 12.1 | 10.9 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
61.7B CNY | -3 036.1 | 21.8 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9B USD | 16.7 | 22.6 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -316.6 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
60B HKD | 0.4 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
Shanghai Universal Biotech Co Ltd
Glance View
Shanghai Universal Biotech Co Ltd is a CN-based company operating in Health Care Providers & Services industry. The company is headquartered in Shanghai, Shanghai and currently employs 493 full-time employees. The company went IPO on 2021-12-28. Shanghai Universal Biotech Co Ltd is a China-based company mainly engaged in the supply of life science reagent products. The firm is also engaged in the supply of life science instruments and consumables and comprehensive technical services. The products supplied by the Company are mainly third-party brand products, supplemented by independent brand products. The life science reagents mainly include immunological reagents based on antibodies and antibody related reagents, as well as molecular biology reagents, cell biology reagents and biochemical reagents. The life science instruments and consumables include detection and analysis and sample preparation. The comprehensive technical services include experimental services, technical support services and other services.
